Human cd30 ligand antigen binding proteins

Abstract

Provided are compositions and methods relating to human CD30L antigen binding proteins Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions Methods of making and using each of these compositions are also provided.

1 . An isolated antigen binding protein that binds CD30L, wherein the antigen binding protein binds a C-terminal region of CD30L defined by AA 201 -234. 
     
     
         2 . An isolated antigen binding protein of  claim 1 , wherein the antigen binding protein binds a further region of CD30L defined by AA 75-95. 
     
     
         3 . An isolated antigen binding protein of  claim 1 , wherein said antigen binding protein has at least one property selected from the group consisting of:
 a) inhibiting CD30/CD30L interaction;   b) inhibiting CD30L-induced IL-8 induction;   c) cross-competing with one of antibodies A-F for binding to human CD30L;   d) a dissociation constant to human CD30L is at most 70 pM and   e) binding to human CD30L with substantially the same or lower Kd as one of antibodies A-F.   
     
     
         4 . An isolated antigen binding protein of any of  claim 1 , wherein the antigen binding protein competes with a Fab of one or more of antibodies A, B, C, D, E and F for binding to CD30L. 
     
     
         5 . An isolated antigen binding protein that binds CD30L, comprising a CDRH1, a CDRH2 and a CDRH3 and a CDRL1, a CDRL2 and a CDRL3,
 wherein CDRL1 is the CDRL1 consensus sequence of SEQ ID NO:30,   wherein CDRL2 is the CDRL2 consensus sequence of SEQ ID NO:31,   wherein CDRL3 is the CDRL3 consensus sequence of SEQ ID NO:32,   wherein CDRH1 is the CDRH1 consensus sequence of SEQ ID NO:33,   wherein CDRH2 is the CDRH2 consensus sequence of SEQ ID NO:34 and   wherein CDRH3 is the CDRH3 consensus sequence of SEQ ID NO:35.   
     
     
         6 . An isolated antigen binding protein of  claim 5  comprising:
 a CDRH1 selected from the group consisting of SEQ ID NOs:14, 15, 16, 17 and 18; 
 a CDRH2 selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23 and 24; a CDRH3 selected from the group consisting of SEQ ID NOs: 25, 26, 27, 28 and 29; 
 a CDRL1 selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5 and 6; 
 a CDRL2 selected from the group consisting of SEQ ID NOs: 7, 8, 9 and 10; 
 and a CDRL3 selected from the group consisting of SEQ ID NOs: 11, 12 and 13. 
 
     
     
         7 . An isolated antigen binding protein of  claim 5  comprising:
 a) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 14, 19, 25 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 1, 7 and 11, 
 b) CDRH 1, CDRH2 and CDRH3 identified by SEQ ID NOs:15, 21, 26 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 2, 8 and 12, 
 c) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs:15, 21, 26 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 3, 8 and 12, 
 d) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs:16, 22, 27 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 4, 9 and 12, 
 e) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs:17, 23, 28 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 5, 8 and 13 or 
 f) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs:1 8, 24, 29 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 6, 10 and 12. 
 
     
     
         8 . An isolated antigen binding protein that binds CD30L selected from the group consisting of:
 a) an isolated antigen binding protein comprising a heavy chain variable region selected from the group consisting of of SEQ ID NOs:48, 50, 52, 54, 56, 58, 60 and 62 and a light chain variable region of SEQ ID NO: 36;   b) an isolated antigen binding protein comprising a heavy chain variable region of SEQ ID NO:64 and a light chain variable region of SEQ ID NO:38;   c) an isolated antigen binding protein comprising a heavy chain variable region of SEQ ID NO:66 and a light chain variable region of SEQ ID NO:40;   d) an isolated antigen binding protein comprising a heavy chain variable region of SEQ ID NO:68 and a light chain variable region of SEQ ID NO:42;   e) an isolated antigen binding protein comprising a heavy chain variable region of SEQ ID NO:70 and a light chain variable region of SEQ ID NO:44; and   f) an isolated antigen binding protein comprising a heavy chain variable region of SEQ ID NO:72 and a light chain variable region of SEQ ID NO:46.   
     
     
         9 . An isolated antigen binding protein of  claim 1 , wherein said antigen binding protein is an antibody. 
     
     
         10 . An isolated antigen binding protein of  claim 9 , wherein said antigen binding protein is of the IgG1-, IgG2- IgG3- or IgG4-type. 
     
     
         11 . A pharmaceutical composition comprising at least one antigen binding protein of  claim 1 , and pharmaceutically acceptable excipient. 
     
     
         12 . A method for treating or preventing a condition associated with CD30L in a patient, comprising administering to a patient in need thereof an effective amount of at least one isolated antigen binding protein of  claim 1 . 
     
     
         13 . A method of reducing CD30L activity in a patient comprising administering an effective amount of at least one antigen binding protein of  claim 1 . 
     
     
         14 . An isolated nucleic acid molecule encoding an antigen binding protein of  claim 1 . 
     
     
         15 . A host cell comprising the nucleic acid molecule of  claim 14 .